Mingqing Wu
Anhui Medical University
6 Papers
Mingqing Wu is an academic researcher from Anhui Medical University. The author has contributed to research in topics: Gene knockdown & SOX2. The author has an hindex of 4, co-authored 4 publications.
Chat about Author
Papers
The m6A methyltransferase METTL3 promotes bladder cancer progression via AFF4/NF-κB/MYC signaling network
Maosheng Cheng,Lu Sheng,Qian Gao,Qiuchan Xiong,Haojie Zhang,Mingqing Wu,Yu Liang,Fengyu Zhu,Yingyin Zhang,Xiuhong Zhang,Quan Yuan,Yang Li +11 more
TL;DR: An AFF4/NF-κB/MYC signaling network operated by METTL3-mediated m6A modification is uncovered and insight into the mechanisms of BCa progression is provided.
395
SOX2 Is a Marker for Stem-like Tumor Cells in Bladder Cancer
Fengyu Zhu,Qian Weiqing,Haojie Zhang,Yu Liang,Mingqing Wu,Yingyin Zhang,Xiuhong Zhang,Qian Gao,Yang Li +8 more
TL;DR: The data show that Sox2 is a marker of bladder CSCs and indicate it as a potential clinical target for BCa therapy, and shows the essential role of SOX2-positive cells in regulating BCa maintenance and progression.
86
JNK Signaling Promotes Bladder Cancer Immune Escape by Regulating METTL3-Mediated m6A Modification of PD-L1 mRNA.
Zegui Ni,Pengli Sun,Mingqing Wu,Congcong Yang,Maosheng Cheng,Mingwei Yin,Chengying Cui,Guangxian Wang,Lin Yuan,Qian Gao,Yang Li +10 more
TL;DR: It is found that activated JNK signaling is associated with increased METTL3 expression in bladder cancer and the identification of a novel m6A-dependent mechanism underlying immune system evasion by bladder cancer cells reveals J NK signaling as a potential target for bladder cancer immunotherapy.
80
Low doses of decitabine improve the chemotherapy efficacy against basal-like bladder cancer by targeting cancer stem cells
Mingqing Wu,Lu Sheng,Maosheng Cheng,Haojie Zhang,Yi-Zhou Jiang,Shuibin Lin,Yu Liang,Fengyu Zhu,Zhenqing Liu,Yingyin Zhang,Xiuhong Zhang,Qian Gao,Demeng Chen,Jiong Li,Jiong Li,Yang Li +15 more
TL;DR: Genetic lineage tracing revealed that the stemness of a bladder cancer stem cell population was inhibited by decitabine treatment in mice, indicating that this DNA-demethylating reagent is a promising therapeutic approach for basal-like bladder cancer treatment.
29
The Expression and Clinical Value of miR-221 and miR-320 in the Plasma of Women with Gestational Diabetes Mellitus.
TL;DR: PlasmamiR-221 and miR-320 are significantly elevated in GDM, and are positively correlated with HbA1c and HOMA-IR and may become a new target for the diagnosis, treatment, and prognosis of GDM.
2